Advaxis, Inc. (ADXS) to Describe ADXS-HPV Clinical Trial Updates in Two Poster Presentations
Advaxis, a clinical-stage biotech company developing next generation immunotherapies for cancer and infectious diseases, will exhibit two abstracts related to ADXS-HPV (ADXS11-001), the company’s lead clinical stage product candidate, in a poster presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 31 – June 4, 2013, at the McCormick Place Convention Center.
Abstract #5529, titled “ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a P2 study in Indian women with recurrent/refractory cervical cancer,” was selected for presentation at the Poster Discussion Session: Gynecologic Cancer. This poster will include updated safety, tumor response, and survival data from the ongoing randomized phase 2 trial of ADXS-HPV with or without cisplatin being conducted by Advaxis in India.
Abstract #TPS3121, titled “A phase 2 study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265),” will be presented during the Developmental Therapeutics – Immunotherapy Trials in Progress General Poster Session. This poster will describe the trial design for the ongoing phase 2 study being conducted by the Gynecologic Oncology Group (GOG) in the United States.
“We are pleased to have the opportunity to present the final 12-month survival and other relevant data from our 110 patient trial of ADXS-HPV in recurrent/refractory cervical cancer at ASCO’s annual meeting,” Dr. Robert Petit, vice president of Clinical Operations and Medical Affairs at Advaxis stated in the press release. “ADXS-HPV immunotherapy offers the promise of an effective and well-tolerated treatment for cervical cancer that employs the patient’s immune system to fight the cancer. We are encouraged by the interest that our colleagues in GOG have in joining our efforts to evaluate the potential of ADXS-HPV in cervical cancer, through the conduct of GOG-0265.”
Abstracts will be released on www.asco.org at 6 p.m. May 15, 2013.
For more information, visit www.advaxis.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net